THE EFFECTIVENESS AND SAFETY OF LOW-DOSE PRAVASTATIN IN ELDERLY HYPERTENSIVE HYPERCHOLESTEROLEMIC SUBJECTS ON ANTIHYPERTENSIVE THERAPY

被引：16

作者：

CHAN, P ^{[1
]}

LEE, CB ^{[1
]}

LIN, TS ^{[1
]}

KO, JT ^{[1
]}

PAN, WH ^{[1
]}

LEE, YS ^{[1
]}

机构：

[1] TAIPEI MUNICIPAL CHUNG HSIAO HOSP,DEPT CARDIOL,CLIN PHARMACOL & THERAPEUT UNIT,TAIPEI,TAIWAN

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1995年 / 8卷 / 11期

关键词：

CHOLESTEROL; PRAVASTATIN; HYPERTENSION; HYPERCHOLESTEROLEMIA;

D O I：

10.1016/0895-7061(95)00229-I

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

To evaluate the efficacy and safety of low dose (10 mg) pravastatin in hypercholesterolemic, hypertensive elderly subjects undergoing antihypertensive treatment, a randomized, double-blind, placebo-controlled 6-month trial was conducted. The subjects had a total plasma cholesterol of at least 250 mg/dL and had been, for at least 3 months, consuming a standard lipid-lowering diet (American Heart Association Step 1 Diet). Sixty elderly hypertensive patients randomly received placebo (n = 30) or pravastatin (n = 30) treatment. The dosage consisted of 10 mg of pravastatin daily during the 6-month trial. Over that period, in the pravastatin group, plasma levels of total cholesterol and LDL-cholesterol significantly (P < .01) dropped (-20% and -25%, respectively) compared to the placebo group. The plasma level of HDL-cholesterol increased (+5%) while triglycerides slightly decreased (-8%) (P < .05). No serious side effects occurred, and pravastatin was generally tolerated. Fasting hyperinsulinemia (11.0 +/- 0.8 v 9.3 +/- 0.7 mu U/mL; P = .06) also improved, although not significantly, after 6 months of pravastatin therapy. Results from this study confirmed that a low dose (10 mg) of pravastatin daily is a safe and effective method of reducing plasma total and LDL-cholesterol in hypercholesterolemic, hypertensive elderly patients who are on concurrent antihypertensive drug therapy.

引用

页码：1099 / 1104

页数：6

共 32 条

[1]

LaRosa, Bush, Criqui, Et al., The cholesterol facts, A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease, 81, pp. 1721-1733, (1990)

[2]

Castelli, Wilson, Levy, Et al., Cardiovascular risk factors in the elderly, The American Journal of Cardiology, 63, pp. 12H-19H, (1989)

[3]

Ettinger, Wahl, Kuller, Et al., Lipoprotein lipids in older people, results from the Cardiovascular Health Study, Circulation, 86, pp. 858-869, (1992)

[4]

Wong, Wilson, Kannel, Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study, Ann Intern Med, 115, pp. 687-693, (1991)

[5]

Pedersen, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, pp. 1383-1389, (1994)

[6]

McTavish, Sorkin, Pravastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolemia, Drugs, 42, pp. 65-89, (1991)

[7]

Jungnickel, Cantral, Maloley, Pravastatin: a new drug for the treatment of hypercholesterolemia, Clin Pharmacy, 11, pp. 677-689, (1992)

[8]

Hunninghake, Knopp, Schonfeld, Et al., Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study, Atherosclerosis, 85, pp. 81-89, (1990)

[9]

Hunninghake, Mellies, Goldberg, Et al., Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once daily versus twice daily dosing, Atherosclerosis, 85, pp. 219-227, (1990)

[10]

Jones, Farmer, Gressman, Et al., Once daily pravastatin in patients with primary hypercholesterolemia: a dose-response study, Clin Cardiol, 14, pp. 146-151, (1991)

← 1 2 3 4 →